A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.
暂无分享,去创建一个
M Sculpher | K Claxton | S. Palmer | M. Sculpher | K. Claxton | Stephen Palmer | Z. Philips | L. Ginnelly | S Palmer | Z Philips | L Ginnelly | Zoë Philips
[1] M. Elman,et al. Earliest symptoms caused by neovascular membranes in the macula. , 1986, Archives of ophthalmology.
[2] N. Bressler,et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.
[3] Gary C. Brown,et al. Utility values associated with blindness in an adult population , 2001, The British journal of ophthalmology.
[4] B. Arant. Vesicoureteric reflux and renal injury. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] 《中华放射肿瘤学杂志》编辑部. Medline , 2001, Current Biology.
[6] O. Salvatierra,et al. The 1989 report of the North American Pediatric Renal Transplant Cooperative Study , 1990, Pediatric Nephrology.
[7] R A Schuchard,et al. Validity and interpretation of Amsler grid reports. , 1993, Archives of ophthalmology.
[8] J Raftery,et al. NICE: faster access to modern treatments? Analysis of guidance on health technologies , 2001, BMJ : British Medical Journal.
[9] J. Dettori,et al. Health technology assessment , 2009, International Journal of Technology Assessment in Health Care.
[10] O. Nielsen,et al. Nitrofurantoin versus Trimethoprim Prophylaxis in Recurrent Urinary Tract Infection in Children , 1990, Acta paediatrica Scandinavica.
[11] R. Grüneberg,et al. CONTROLLED TRIAL OF PROPHYLACTIC TREATMENT IN CHILDHOOD URINARY-TRACT INFECTION , 1978, The Lancet.
[12] M Johannesson,et al. On the decision rules of cost-effectiveness analysis. , 1993, Journal of health economics.
[13] J. Craig,et al. Long-term antibiotics for preventing recurrent urinary tract infection in children. , 2019, The Cochrane database of systematic reviews.
[14] S Senn,et al. Analysis of serial measurements in medical research. , 1990, BMJ.
[15] G. Howie,et al. CONTROLLED TRIAL OF THERAPY IN COVERT BACTERIURIA OF CHILDHOOD , 1975, The Lancet.
[16] M J Al,et al. Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.
[17] Paul Kind,et al. A social tariff for EuroQol: results from a UK general population survey , 1995 .
[18] Border Ireland,et al. Chartered Institute of Public Finance and Accountancy (CIPFA) , 2006 .
[19] E. Stokland,et al. The natural history of bacteriuria in childhood. , 1997, Infectious disease clinics of North America.
[20] J. Stansfeld. Duration of treatment for urinary tract infections in children. , 1975, British medical journal.
[21] J. Pater. Quality of life and pharmacoeconomics in clinical trials , 1996 .
[22] S. Downs. Technical Report: Urinary Tract Infections in Febrile Infants and Young Children , 1999, Pediatrics.
[23] A. Bird,et al. Senile disciform macular degeneration in the second eye. , 1977, The British journal of ophthalmology.
[24] LASER TREATMENTS WITH VERTEPORFIN THERAPY AND ITS POTENTIAL IMPACT ON RETINAL PRACTICES , 2000, Retina.
[25] J. Winberg,et al. Morbidity, age and sex distribution, recurrences and renal scarring in symptomatic urinary tract infection in childhood. , 1975, Kidney international. Supplement.